Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

CID to Update Interventional Cardiologists on Their Drug Eluting Stent Program at TCT 2010

September 16, 2010 By Bio-Medicine.Org

WASHINGTON, Sept. 16 /PRNewswire/ — CID s.r.l., a European
company leader in interventional medicine, will update
interventional cardiologists on the status of their revolutionary
drug eluting stent technology during The Drug Eluting Stent (DES)
Summit at TCT 2010, Washington, DC on Wednesday, September 22,
2010.  The lecture, entitled “Status of the CID Cre8
polymer-free DES program”, will be delivered by Alexandre Abizaid,
MD, PhD. Chief of Intervention at Instituto Dante Pazzanese, in Sao
Paulo Brazil, and will be part of the session “The Next Generation
DES, Polymer-Free”.

Some of the highlights of the presentation will include an
exploration of the clinical benefits of CID’s Abluminal Reservoir
Technology (ART) and drug delivery technology. By surrounding
molecules of drug with amphiphilic carriers and embedding them into
reservoirs on the stent’s outer surface, CID drug-eluting stents
are able to deliver drug to the coronary arteries without using any
polymers, which can cause serious complications in patients.

CID’s unique ART system with its amphiphilic carrier is more
physiological and patients who receive these stents are less likely
to have inflammation and thrombosis within their coronary arteries.
Moreover CID DES technology features an integral Bio-Inducer
Surface (BIS) which implies less medication to prevent blood
clotting after the stent has been deployed for enhanced safety.

Commenting on the innovative technology in its new Cre8 DES,
Franco Vallana, Chief Executive Officer of CID s.r.l. said, “We
have always known that the more the stent and the drug delivery
system are designed and developed to harmonize with the human body,
the better the short- and long-term results will be. Combining ART
with our innovative drug formulation with amphiphilic carrier into
a completely polymer-free stent will allow doctors to provide their
patients with stents that are more physiological and complement the
body’s natural systems.” </

‘/>”/>

SOURCE

Related Articles Read More >

A portrait of ResMed President and COO Rob Douglas
ResMed finds a solution to semiconductor shortage, as well as some humor in it
Johnson & Johnson Office of Digital Innovation Leader Peter Schulam
Imagining the future of cloud-connected medical devices with Johnson & Johnson leaders
Withings Body Scan
Withings plans launch for Body Scan smart scale platform
BinaxNow COVID-19 Ag Card
Time recognizes Abbott offerings among this year’s 100 best inventions

DeviceTalks Weekly.

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech